Incyte Corp v. Encube Ethicals Pvt Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Incyte Corp. and Incyte Holdings Corp. (Delaware)
  • Defendant: Encube Ethicals Pvt. Ltd. (India)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: 2:26-cv-00539, D.N.J., 08/24/2026
• Venue Allegations: Plaintiff alleges venue is proper because Defendant is a corporation organized under the laws of India and may be sued in any judicial district. The District of New Jersey is also alleged to be a likely destination for the accused product.
• Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of Plaintiff's Opzelura® (ruxolitinib) cream infringes eleven U.S. patents directed to pharmaceutical formulations and methods of use.
• Technical Context: The technology at issue involves topical pharmaceutical formulations of ruxolitinib, a Janus kinase (JAK) inhibitor, used for the treatment of skin disorders such as atopic dermatitis and vitiligo.
• Key Procedural History: The action was initiated under the Hatch-Waxman Act following Defendant's submission of ANDA No. 218765 and its subsequent delivery of Paragraph IV certification notice letters to Plaintiff, alleging that the patents-in-suit are invalid and/or will not be infringed by the proposed generic product.

Case Timeline

Date	Event
2010-05-21	Earliest Priority Date for '543, '870, '624, '425, '136, '419, '381, '593 Patents
2019-09-05	Earliest Priority Date for '923, '137, '096 Patents
2020-09-01	U.S. Patent No. 10,758,543 Issues
2020-12-22	U.S. Patent No. 10,869,870 Issues
2022-01-11	U.S. Patent No. 11,219,624 Issues
2022-11-29	U.S. Patent No. 11,510,923 Issues
2023-02-07	U.S. Patent No. 11,571,425 Issues
2023-02-28	U.S. Patent No. 11,590,136 Issues
2023-02-28	U.S. Patent No. 11,590,137 Issues
2025-02-18	U.S. Patent No. 12,226,419 Issues
2025-12-01	Defendant Sent First Paragraph IV Notice Letter to Plaintiff
2026-02-10	U.S. Patent No. 12,544,381 Issues
2026-03-03	U.S. Patent No. 12,564,593 Issues
2026-03-31	U.S. Patent No. 12,589,096 Issues
2026-04-08	Defendant Sent Second Paragraph IV Notice Letter to Plaintiff
2026-07-24	Defendant Sent Third Paragraph IV Notice Letter to Plaintiff
2026-08-24	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,758,543 - "Topical Formulation for a JAK Inhibitor"

The Invention Explained

• Problem Addressed: The patent addresses the need for improved topical formulations of Janus kinase (JAK) inhibitors for treating skin disorders, noting a need for formulations that are stable, easily applied, and have good skin permeation characteristics ʼ543 Patent, col. 2:31-38
• The Patented Solution: The invention is an oil-in-water emulsion containing the JAK inhibitor ruxolitinib, formulated as a "solubilized cream" suitable for topical application ʼ543 Patent, abstract This formulation is described as having superior spreadability, stability, and skin permeation compared to other formulations like anhydrous ointments or water-in-oil emulsions ʼ543 Patent, col. 4:29-39 The manufacturing process is depicted in a flowchart ʼ543 Patent, FIG. 1
• Technical Importance: This formulation provided a stable and effective vehicle for delivering a JAK inhibitor topically to treat skin immune disorders such as psoriasis ʼ543 Patent, col. 2:10-14

Key Claims at a Glance

• The complaint asserts one or more claims of the patent Compl. ¶38 Independent claim 1 is representative:
• Claim 1: A pharmaceutical composition suitable for topical skin application, comprising:
  • an oil-in-water emulsion, comprising: water; an oil component; an emulsifier component; a solvent component, and
  • from about 0.5% to about 1.5% by weight of the emulsion on a free base basis of 1:1 (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl-]propanenitrile phosphoric acid salt,
  • wherein the oil-in-water emulsion in the composition is a solubilized cream for topical skin application and
  • further wherein the oil-in-water emulsion has a pH of not greater than 3.6.

U.S. Patent No. 10,869,870 - "Topical Formulation for a JAK Inhibitor"

The Invention Explained

• Problem Addressed: The patent discloses the need for effective treatments for skin disorders, including autoimmune diseases, which can be addressed by inhibiting JAK kinases ʼ870 Patent, col. 1:11-17 ʼ870 Patent, col. 2:32-38
• The Patented Solution: The patent claims a method of treating skin disorders by applying a specific oil-in-water topical formulation of the JAK inhibitor ruxolitinib ʼ870 Patent, abstract The specification notes that this type of formulation was found to have good stability and better skin permeation characteristics compared to water-in-oil or anhydrous formulations, which is critical for effective topical drug delivery ʼ870 Patent, col. 4:29-54
• Technical Importance: The claimed method provides a way to use a specific, stable ruxolitinib formulation to treat autoimmune skin disorders, which are characterized by an inappropriate immune or inflammatory response ʼ870 Patent, col. 1:44-48

Key Claims at a Glance

• The complaint asserts one or more claims of the patent Compl. ¶47 Independent claim 1 is representative:
• Claim 1: A method of treating a skin disorder in a human patient in need thereof, comprising:
  • applying to the patient's skin a pharmaceutically acceptable composition comprising: an oil-in-water emulsion, comprising: water, an oil component, an emulsifier component, a solvent component, and
  • from about 0.5% to about 1.5% by weight of the emulsion on a free base basis of 1:1 (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphoric acid salt,
  • wherein the oil-in-water emulsion in the composition is a solubilized cream and has a pH of not greater than 3.6;
  • wherein treating is one or more of inhibiting the skin disorder and ameliorating the skin disorder; and
  • wherein the skin disorder is an autoimmune skin disorder.

U.S. Patent No. 11,219,624 - "Topical Formulation for a JAK Inhibitor"

• Technology Synopsis: This patent, related to the '543 and '870 patents, is also directed to oil-in-water cream formulations of ruxolitinib for topical skin application ʼ624 Patent, abstract It addresses the need for stable and effective topical JAK inhibitor formulations to treat skin disorders like psoriasis ʼ624 Patent, col. 2:31-38
• Asserted Claims: The complaint asserts one or more claims of the patent Compl. ¶56
• Accused Features: The accused instrumentality is Encube's Proposed Generic Product, the subject of ANDA No. 218765 (Compl. ¶¶25; Compl. ¶29).

U.S. Patent No. 11,510,923 - "Ruxolitinib Formulation for Reduction of Itch in Atopic Dermatitis"

• Technology Synopsis: This patent claims methods of reducing itch associated with atopic dermatitis by administering a topical ruxolitinib cream ʼ923 Patent, abstract The patent describes the clinical need for treatments that can promptly and effectively control itch, which is a cardinal feature of atopic dermatitis and leads to a high disease burden ʼ923 Patent, col. 1:43-52
• Asserted Claims: The complaint asserts one or more claims of the patent Compl. ¶65
• Accused Features: The accused instrumentality is Encube's Proposed Generic Product, the subject of ANDA No. 218765 (Compl. ¶¶25; Compl. ¶29).

U.S. Patent No. 11,571,425 - "Topical Formulation for a JAK Inhibitor"

• Technology Synopsis: This patent is directed to a specific oil-in-water pharmaceutical formulation for topical skin application containing ruxolitinib ʼ425 Patent, abstract The formulation is designed to provide a stable and effective vehicle for delivering a JAK inhibitor to treat skin disorders ʼ425 Patent, col. 2:31-38
• Asserted Claims: The complaint asserts one or more claims of the patent Compl. ¶74
• Accused Features: The accused instrumentality is Encube's Proposed Generic Product, the subject of ANDA No. 218765 (Compl. ¶¶25; Compl. ¶29).

U.S. Patent No. 11,590,136 - "Topical Formulation for a JAK Inhibitor"

• Technology Synopsis: This patent claims an oil-in-water emulsion formulation of ruxolitinib for topical skin application with specific weight percentage ranges for its components '136 Patent, abstract '136 Patent, claim 1 The formulation is described as a solubilized cream with a pH not greater than 3.6, intended to provide a stable and effective topical treatment for skin disorders '136 Patent, col. 2:31-38
• Asserted Claims: The complaint asserts one or more claims of the patent Compl. ¶83
• Accused Features: The accused instrumentality is Encube's Proposed Generic Product, the subject of ANDA No. 218765 (Compl. ¶¶25; Compl. ¶29).

U.S. Patent No. 11,590,137 - "Ruxolitinib Formulation for Reduction of Itch in Atopic Dermatitis"

• Technology Synopsis: This patent is directed to methods of treating moderate atopic dermatitis by administering a topical ruxolitinib cream, where the patient meets certain clinical criteria such as a minimum Body Surface Area (BSA) of involvement and a minimum itch score '137 Patent, abstract '137 Patent, claim 1 The methods are intended to provide prompt and effective control of itch '137 Patent, col. 1:43-52
• Asserted Claims: The complaint asserts one or more claims of the patent Compl. ¶92
• Accused Features: The accused instrumentality is Encube's Proposed Generic Product, the subject of ANDA No. 218765 (Compl. ¶¶25; Compl. ¶29).

U.S. Patent No. 12,226,419 - "Topical Formulation for a JAK Inhibitor"

• Technology Synopsis: This patent covers an oil-in-water emulsion formulation of ruxolitinib with specific component categories and a defined pH range ʼ419 Patent, claim 1 Like the other formulation patents, it aims to provide a stable and effective topical delivery system for treating skin disorders ʼ419 Patent, col. 2:31-38
• Asserted Claims: The complaint asserts one or more claims of the patent Compl. ¶101
• Accused Features: The accused instrumentality is Encube's Proposed Generic Product, the subject of ANDA No. 218765 (Compl. ¶¶25; Compl. ¶29).

U.S. Patent No. 12,544,381 - "Topical Formulation for JAK Inhibitor"

• Technology Synopsis: This patent claims specific oil-in-water cream formulations of ruxolitinib defined by the weight percentages of various components, including water, petrolatum, cetyl alcohol, and stearyl alcohol ʼ381 Patent, claim 16 The formulation is designed to be a stable vehicle for topical delivery to treat skin disorders '381 Patent, col. 2:31-38
• Asserted Claims: The complaint asserts one or more claims of the patent Compl. ¶110
• Accused Features: The accused instrumentality is Encube's Proposed Generic Product, the subject of ANDA No. 218765 (Compl. ¶¶25; Compl. ¶29).

U.S. Patent No. 12,564,593 - "Topical Formulation for a JAK Inhibitor"

• Technology Synopsis: This patent describes methods of treating skin disorders by applying a specific oil-in-water ruxolitinib cream '593 Patent, abstract The method claims are directed at inhibiting or ameliorating an autoimmune skin disorder '593 Patent, claim 1
• Asserted Claims: The complaint asserts one or more claims of the patent Compl. ¶119
• Accused Features: The accused instrumentality is Encube's Proposed Generic Product, the subject of ANDA No. 218765 (Compl. ¶¶25; Compl. ¶29).

U.S. Patent No. 12,589,096 - "Ruxolitinib Formulation for Reduction of Itch in Atopic Dermatitis"

• Technology Synopsis: This patent claims methods for reducing itch in patients with atopic dermatitis by applying a topical ruxolitinib cream, wherein the patient achieves a specified reduction in their itch score from baseline '096 Patent, abstract The methods are intended to address the significant disease burden caused by itch in atopic dermatitis patients '096 Patent, col. 1:43-52
• Asserted Claims: The complaint asserts one or more claims of the patent Compl. ¶128
• Accused Features: The accused instrumentality is Encube's Proposed Generic Product, the subject of ANDA No. 218765 (Compl. ¶¶25; Compl. ¶29).

III. The Accused Instrumentality

Product Identification

• The accused instrumentality is "Encube's Proposed Generic Product," which is the subject of Abbreviated New Drug Application (ANDA) No. 218765 submitted to the FDA Compl. ¶25 Compl. ¶29

Functionality and Market Context

• The complaint alleges that the Proposed Generic Product is a generic version of Incyte's Opzelura® (ruxolitinib) cream, a topical treatment for mild to moderate atopic dermatitis and nonsegmental vitiligo Compl. ¶1 Compl. ¶19 Compl. ¶20 The complaint does not contain specific details regarding the formulation of the accused product, as such information is typically confidential within the ANDA. Plaintiff alleges that upon FDA approval, Defendant intends to manufacture, use, import, distribute, offer to sell, and sell the product in the United States Compl. ¶25 Compl. ¶27 Compl. ¶30
  No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide a detailed mapping of claim elements to specific features of the accused product, which is common in initial pleadings for ANDA litigation. The central infringement allegation is that Defendant's submission of ANDA No. 218765 seeking approval to market a generic version of Opzelura® cream before the expiration of the patents-in-suit constitutes a statutory act of infringement under 35 U.S.C. § 271(e)(2)(A) Compl. ¶38 Compl. ¶47 This legal theory presumes that the proposed generic product, to secure FDA approval, will necessarily have the same active ingredient, dosage form, and strength as the branded product and will be used for the same indications, thereby practicing the asserted composition and method claims. The complaint does not provide sufficient detail for a claim chart-based analysis.

• Identified Points of Contention:
  • Scope Questions: A central question for the composition claims (e.g., in the '543 Patent) will be whether the specific excipients and physical properties of Defendant's formulation, as detailed in its confidential ANDA, fall within the scope of claim terms such as "solubilized cream," "oil component," "emulsifier component," and the pH limitation of "not greater than 3.6."
  • Technical Questions: For the method-of-use claims (e.g., in the '870 Patent), a key issue may be whether the product label proposed in the ANDA will instruct or encourage physicians and patients to administer the generic product in a manner that directly infringes the claimed methods, such as for treating an "autoimmune skin disorder."

V. Key Claim Terms for Construction

• The Term: "solubilized cream" (from Claim 1 of the '543 Patent)

• Context and Importance: This term describes the physical state of the claimed pharmaceutical composition. Practitioners may focus on this term because the distinction between a "solubilized cream" (where the active ingredient is dissolved) and a dispersion or suspension could be a critical, dispositive issue for infringement. The defendant may argue its formulation is not a "solubilized cream" to avoid literal infringement.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specification contrasts the claimed oil-in-water formulations with water-in-oil formulations where the active pharmaceutical ingredient (API) "dissolved in the base over time, leading to highly variable skin permeation" ʼ543 Patent, col. 4:55-60 This suggests "solubilized" is meant to distinguish from unstable or variable formulations, potentially broadening the term to cover any stable, dissolved state in an oil-in-water cream.
  • Evidence for a Narrower Interpretation: Example 3 of the patent describes the preparation of specific "Oil-In-Water Cream Formulations" ʼ543 Patent, col. 20:47-51 Parties may argue that the term "solubilized cream" should be construed in light of this specific example, potentially limiting its scope to creams with similar components and manufacturing processes.

• The Term: "pH of not greater than 3.6" (from Claim 1 of the '543 Patent)

• Context and Importance: This numerical limitation defines a required chemical property of the final formulation. The infringement analysis will depend on whether the accused product meets this precise pH threshold. Disputes may arise over the method and timing of pH measurement (e.g., at the time of manufacture vs. throughout the product's shelf life).

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The plain language "not greater than" establishes a clear upper limit, which could be interpreted to mean any pH value at or below 3.6, measured under standard conditions, falls within the claim scope.
  • Evidence for a Narrower Interpretation: The stability data presented in the patent's tables show formulations with pH values tested between 3.1 and 3.6 ʼ543 Patent, Table 6 A defendant may argue that this range represents the operative and stable embodiment of the invention, suggesting the claim should be limited to a pH that is also demonstrably stable, rather than any transient measurement below 3.6.

VI. Other Allegations

• Indirect Infringement: Plaintiff alleges both induced and contributory infringement for all asserted patents. The inducement allegations are based on Defendant's alleged knowledge of the patents and its intent to encourage infringing acts by marketing the generic product for uses covered by the patents Compl. ¶41 Compl. ¶50 These allegations appear to rely on the future product label instructing users to perform the claimed methods Compl. ¶¶19-21 Contributory infringement is alleged on the basis that the proposed generic product is especially adapted for an infringing use and has no substantial non-infringing use Compl. ¶42 Compl. ¶51
• Willful Infringement: The complaint does not explicitly use the term "willful infringement," but it does allege that Defendant had knowledge of the patents-in-suit via multiple Paragraph IV notice letters sent between December 2025 and July 2026 (Compl. ¶¶32; Compl. ¶34; Compl. ¶36). Plaintiff seeks an award of attorneys' fees under 35 U.S.C. § 285, alleging the case is "exceptional" Compl. ¶45 Compl. ¶54

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of definitional scope: can the term "solubilized cream," as defined by the patent's specification and examples, be construed to read on the specific formulation disclosed in Defendant's confidential ANDA, or will Defendant be able to establish a fundamental difference in the formulation's physical or chemical properties?
• A second key question will be one of infringement of method claims: for patents claiming methods of treatment (e.g., '870, '923, '137, '096 patents), will the proposed label for Defendant's generic product provide sufficient evidence of intent to induce infringement by encouraging physicians and patients to use the product for the patented indications, such as reducing itch in atopic dermatitis?
• Finally, a central evidentiary question will be one of equivalence: if Defendant's formulation does not literally infringe the composition claims, does it contain components that perform substantially the same function, in substantially the same way, to achieve substantially the same result as the claimed elements, raising a question of infringement under the doctrine of equivalents?